Login to Your Account

Genzyme's Mozobil Phase III Positive In NHL; MM To Come

By Randall Osborne

Friday, July 20, 2007
Genzyme Corp.'s Phase III win with Mozobil (plerixafor) for non-Hodgkin's lymphoma vindicates those who cheered the high-priced buyout in a bidding war for AnorMED Inc., but the market for the CXCR4 chemokine antagonist might not be huge, and investors still are waiting for results of the trial in multiple myeloma, due in the next few weeks.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription